Information for Authors - - BioPharm International

ADVERTISEMENT

Information for Authors

BioPharm International

BioPharm International’s readers are also its authors. You can help us meet your needs by submitting manuscripts that offer technical and scientific discussions of ongoing drug development challenges and solutions.

Submitted manuscripts should be sufficiently novel to be of interest to an experienced audience. Articles should be data driven and provide sufficient technical detail to support the main thesis or should offer a novel synthesis of existing data. Topics should be timely and useful and should focus on the development of peptides, monoclonal antibodies, fusion proteins, other therapeutic proteins, nucleic acids, vaccines, cells for cell therapy, and any other class of biotechnologically generated molecular class.

Peer-review Articles
Articles submitted for peer review may fall into four main categories: standard data-driven, novel research paper; topical literature or patent review; technical case studies/technical application notes; and science-based opinion papers. See the author guidelines for peer-review papers for details.

BioPharm International will consider original technical and scientific review articles that have never been previously published in any format, print or electronic, and are not under consideration at any other journal during the period they’re under review at BioPharm International.

To contribute, view BioPharm International's Author Guidelines for Peer-Review Papers - 2014 or Author Guidelines for Supplements and Technical Articles [downloadable PDFs].

View the 2014 Editorial Calendar.

View the 2015 Editorial Calendar.

 

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here